当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia.

Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia.

Abstract：

:Ninety-five percent of radiation-induced murine myeloid leukemias contain chromosome 2 aberrations. A dominant molecular defect has not yet been identified: both deletions and breakpoint-specific events have been postulated. We have generated a model in which chromosome 2 lesions have been generated in vitro in a clonal tumor cell line. In this study cytogenetic and molecular comparisons are made between two of these in vitro generated lesions and eight derived in vivo: seven by the conventional radiation protocol, and one by infection with Moloney leukemia virus. All 10 lines consistently exhibited hemizygous loss of an 18 cM region between Hoxd-4 and II-1 alpha, with variable breakpoints at both ends. These results are consistent with deletion of a gene in common rather than breakpoint-specific events, for lesions resulting from all three protocols. This will allow a novel approach to the identification of a putative tumor suppressor gene, ie to describe the biological effect of the in vitro generated deletion, and to clone the gene by complementation. In preparation for this approach, we have further narrowed the region to approximately 6.5 cM by microsatellite mapping of 22 radiation-induced F1 tumors. In addition, we have eliminated the possibility that imprinting ablates expression from the remaining undeleted chromosome.

journal_name

Leukemia

journal_title

Leukemia

authors

Alexander BJ,Rasko JE,Morahan G,Cook WD

subject

Has Abstract

pub_date

1995-12-01 00:00:00

pages

2009-15

issue

12

eissn

0887-6924

issn

1476-5551

journal_volume

9

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells.

    abstract：:Tumor cells in chronic lymphocytic leukemia (CLL) are more prone to apoptosis when cultured ex vivo, because they lack prosurvival signals furnished in vivo via B-cell receptor (BCR)-dependent and -independent pathways. This study compared the susceptibility of unmutated (UM) and mutated (M) CLL B cells to spontaneous...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.12

    authors： Coscia M,Pantaleoni F,Riganti C,Vitale C,Rigoni M,Peola S,Castella B,Foglietta M,Griggio V,Drandi D,Ladetto M,Bosia A,Boccadoro M,Massaia M

    更新日期：2011-05-01 00:00:00

  • Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+ T cells.

    abstract：:On activation, umbilical cord blood (UCB) CD4(+) T cells demonstrate reduced expression of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma), whereas maintaining equivalent interleukin-2 (IL-2) levels, as compared with adult peripheral blood (PB) CD4(+) T cells. Nuclear factor of activated T cel...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.234

    authors： Lesniewski ML,Haviernik P,Weitzel RP,Kadereit S,Kozik MM,Fanning LR,Yang YC,Hegerfeldt Y,Finney MR,Ratajczak MZ,Greco N,Paul P,Maciejewski J,Laughlin MJ

    更新日期：2008-12-01 00:00:00

  • Detection of p53 mutations in B cell non-Hodgkin's lymphoma cell lines.

    abstract：:The p53 tumor suppressor gene is frequently mutated within its evolutionarily conserved regions in a number of human cancers. Previous reports demonstrated mutations of this gene in both Burkitt's lymphoma and B cell chronic lymphocytic leukemia. However, dissimilar results were obtained in non-Hodgkin's lymphoma (NHL...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Li CC,O'Connell CD,Beckwith M,Longo DL

    更新日期：1995-04-01 00:00:00

  • New roles for B cell receptor associated kinases: when the B cell is not the target.

    abstract：:Targeting of B cell receptor associated kinases (BAKs), such as Bruton's tyrosine kinase (BTK) or phosphoinositol-3-kinase (PI3K) delta, by specific inhibitors has revolutionized the therapy of B lymphoid malignancies. BAKs are critical signaling transducers of BCR signaling and seem relevant in B cell lymphoma pathog...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0366-8

    authors： Nguyen PH,Niesen E,Hallek M

    更新日期：2019-03-01 00:00:00

  • Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma.

    abstract：:Primary effusion lymphoma (PEL) is a fatal malignancy, which typically presents as a lymphomatous effusion that later disseminates. Rapamycin (Rapa), which targets mTOR (mammalian target of Rapa), is currently evaluated as a treatment for PEL, but the recent development of PEL in Rapa-treated post-transplant recipient...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.117

    authors： Gasperini P,Tosato G

    更新日期：2009-10-01 00:00:00

  • Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1*0601.

    abstract：:We previously reported that susceptibility to childhood B cell precursor ALL (BCP ALL) is associated with HLA-DPB1 alleles having glutamic acid (E) rather than lysine (K) in the P4 antigenic peptide-binding pocket. Clustering approximately 90% of DPB1 alleles into DPB69E (DP2, 6, 8) and DPB69K (DP1, 3, 4) supertypes r...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.374

    authors： Taylor GM,Hussain A,Verhage V,Thompson PD,Fergusson WD,Watkins G,Lightfoot T,Harrison CJ,Birch JM,UKCCS Investigators.

    更新日期：2009-05-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract：:We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402996

    authors： Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期：2003-08-01 00:00:00

  • Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.

    abstract：:Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404734

    authors： Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

    更新日期：2007-07-01 00:00:00

  • Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

    abstract：:Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduce...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.183

    authors： Versluis J,In 't Hout FE,Devillier R,van Putten WL,Manz MG,Vekemans MC,Legdeur MC,Passweg JR,Maertens J,Kuball J,Biemond BJ,Valk PJ,van der Reijden BA,Meloni G,Schouten HC,Vellenga E,Pabst T,Willemze R,Löwenberg B,O

    更新日期：2017-01-01 00:00:00

  • Detection of trisomy 8 on blood smears using fluorescence in situ hybridization.

    abstract：:In this study, fluorescence in situ hybridization (ISH) with an alphoid probe was used for the detection of trisomy 8 on archival blood smears (BS). The results were compared with hybridization experiments performed on methanol/acetic acid fixed cells of cytogenetic preparations (CP) which are widely used for ISH. Fiv...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Bentz M,Schröder M,Herz M,Stilgenbauer S,Lichter P,Döhner H

    更新日期：1993-05-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402150

    authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期：2001-08-01 00:00:00

  • Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.

    abstract：:As typical disorders of the elderly, myelodysplastic syndromes (MDSs) are relatively unusual in childhood. Nevertheless, up to 17% of cases of pediatric acute myeloid leukemia may have a preleukemic phase. In young patients, the goal of treatment is eradication of the preleukemic malignant clone and reconstitution of ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Locatelli F,Pession A,Bonetti F,Maserati E,Prete L,Pedrazzoli P,Zecca M,Prete A,Paolucci P,Cazzola M

    更新日期：1994-05-01 00:00:00

  • Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis.

    abstract：:Conditionally replicating adenoviruses (CRAds) represent a promising new platform for anticancer therapy. However, CRAds have been evaluated little in hematopoietic malignancies because of the lack of expression of coxsackie adenovirus receptor (CAR) on their cell surface. In this study, we showed that CAR was express...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2405034

    authors： Qian W,Liu J,Tong Y,Yan S,Yang C,Yang M,Liu X

    更新日期：2008-02-01 00:00:00

  • BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

    abstract：:Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.358

    authors： Cheng S,Ma J,Guo A,Lu P,Leonard JP,Coleman M,Liu M,Buggy JJ,Furman RR,Wang YL

    更新日期：2014-03-01 00:00:00

  • Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox).

    abstract：:Schedule dependency of idarubicin (Ida) and doxorubicin (Dox) toxicity was investigated in vitro using the K562 human leukemia cell line. For Dox, repeated exposure to the IC30 (d x 3) resulted in comparable survival as single exposure to the total accumulative dose (20%). For Ida, repeated exposure to the IC30 (d x 3...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Minderman H,Buscaglia MD,Rustum YM

    更新日期：1994-08-01 00:00:00

  • Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery.

    abstract：:Membrane-derived vesicles (MV) are released from the surface of activated eucaryotic cells and exert pleiotropic effects on surrounding cells. Since the maintenance of pluripotency and undifferentiated propagation of embryonic stem (ES) cells in vitro requires tight cell to cell contacts and effective intercellular si...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404132

    authors： Ratajczak J,Miekus K,Kucia M,Zhang J,Reca R,Dvorak P,Ratajczak MZ

    更新日期：2006-05-01 00:00:00

  • Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients.

    abstract：:Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40% of patients. The ai...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41375-019-0644-0

    authors： Barilà G,Teramo A,Calabretto G,Vicenzetto C,Gasparini VR,Pavan L,Leoncin M,Vedovato S,Frigo AC,Facco M,Semenzato G,Zambello R

    更新日期：2020-04-01 00:00:00

  • Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes.

    abstract：:B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5(+) B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404185

    authors： Mous R,Savage P,Remmerswaal EB,van Lier RA,Eldering E,van Oers MH

    更新日期：2006-06-01 00:00:00

  • Cryptic insertion and translocation or nondividing leukemic cells disclosed by FISH analysis in infant acute leukemia with discrepant molecular and cytogenetic findings.

    abstract：:Of 51 infants with acute leukemia, 13 (25%) had contradictory findings on 11q23/MLL rearrangements that were analyzed by cytogenetic and Southern blot methods: seven had rearranged MLL and normal karyotype, four had rearranged MLL and abnormal karyotype with no 11q23 translocation, and two had germline MLL and 11q23 t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402900

    authors： Watanabe N,Kobayashi H,Ichiji O,Yoshida MA,Kikuta A,Komada Y,Sekine I,Ishida Y,Horiukoshi Y,Tsunematsu Y,Yano M,Nakadate H,Kaneko Y

    更新日期：2003-05-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract：:We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期：1994-01-01 00:00:00

  • Immunoglobulin prophylaxis against HTLV-I in a rabbit model.

    abstract：:We have investigated the protective effect of human T-cell leukemia virus I (HTLV-I) immune globulin (HTLVIG) against HTLV-I in rabbits. HTLVIG containing 77 mg/ml of IgG was prepared from pooled plasma from seropositive healthy persons. In the first experiment, four groups (A, B, C, and D) of three rabbits were trans...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Miyoshi I,Takehara N,Sawada T,Iwahara Y,Kataoka R,Yang D,Hoshino H

    更新日期：1992-01-01 00:00:00

  • Validity of the in vitro system as a correlate of the in vivo model of RadLV lymphomagnesis.

    abstract：:Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Haran-Ghera N,Peled A

    更新日期：1991-06-01 00:00:00

  • Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

    abstract：:We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients bein...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-01031-1

    authors： Largeaud L,Cornillet-Lefebvre P,Hamel JF,Dumas PY,Prade N,Dufrechou S,Plenecassagnes J,Luquet I,Blanchet O,Banos A,Béné MC,Bernard M,Bertoli S,Bonmati C,Fornecker LM,Guièze R,Haddaoui L,Hunault M,Ianotto JC,Jourdan

    更新日期：2020-09-18 00:00:00

  • Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.

    abstract：:Patients with normal-karyotype acute myelogenous leukemia (NKAML) may have undetected genetic abnormalities that could affect prognosis. Screening for known AML-specific genetic abnormalities using the reverse transcription polymerase chain reaction (RT-PCR) may help in arriving at a more definitive prognosis. To test...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401951

    authors： Sarriera JE,Albitar M,Estrov Z,Gidel C,Aboul-Nasr R,Manshouri T,Kornblau S,Chang KS,Kantarjian H,Estey E

    更新日期：2001-01-01 00:00:00

  • Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.

    abstract：:Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common gamma-chain (IL2RG), the coding sequence...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.118

    authors： Modlich U,Schambach A,Brugman MH,Wicke DC,Knoess S,Li Z,Maetzig T,Rudolph C,Schlegelberger B,Baum C

    更新日期：2008-08-01 00:00:00

  • Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

    abstract：:The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.10

    authors： Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

    更新日期：2013-06-01 00:00:00

  • Genetic predisposition for multiple myeloma.

    abstract：:Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun to provide direct...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-019-0703-6

    authors： Pertesi M,Went M,Hansson M,Hemminki K,Houlston RS,Nilsson B

    更新日期：2020-03-01 00:00:00

  • Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

    abstract：:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.46

    authors： Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

    更新日期：2017-10-01 00:00:00

  • Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

    abstract：:Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal evolution likely has therapeutic implications but its dynamic is less well studied. We studied clonal composition and prognostic value of seven recurrently mutated driv...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0215-9

    authors： Leeksma AC,Taylor J,Wu B,Gardner JR,He J,Nahas M,Gonen M,Alemayehu WG,Te Raa D,Walther T,Hüllein J,Dietrich S,Claus R,de Boer F,de Heer K,Dubois J,Dampmann M,Dürig J,van Oers MHJ,Geisler CH,Eldering E,Levine RL

    更新日期：2019-02-01 00:00:00

  • BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

    abstract：:Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia. However, patients with a potential for cure are at risk of severe acute and late adverse effects of treatment. Furthermore, in 25-30% of pati...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1038/sj.leu.2402489

    authors： Kamps WA,Bökkerink JP,Hakvoort-Cammel FG,Veerman AJ,Weening RS,van Wering ER,van Weerden JF,Hermans J,Slater R,van den Berg E,Kroes WG,van der Does-van den Berg A

    更新日期：2002-06-01 00:00:00